Showing results (141-150 of 195) with videos related to
Sort By:
Pageof 20
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 4, 2008
Cyclophosphamide facilitates antitumor efficacy against subcutaneous tumors following intravenous delivery of reovirusJian Qiao, Hongxun Wang, Timothy Kottke, et al.Nature Medicine|June 21, 2011
Broad antigenic coverage induced by vaccination with virus-based cDNA libraries cures established tumorsTimothy Kottke, Fiona Errington, Jose Pulido, et al.Cell Stress & Chaperones|May 10, 2008
An animal model to evaluate the function and regulation of the adaptively evolving stress protein SEP53 in oesophageal bile damage responsesLenny Nelson, Susan Anderson, Alan L Archibald, et al.Ecology|May 26, 2012
Temporal turnover in the composition of tropical tree communities: functional determinism and phylogenetic stochasticityNathan G Swenson, James C Stegen, Stuart J Davies, et al.Neuro-Oncology|September 28, 2015
Combination viroimmunotherapy with checkpoint inhibition to treat glioma, based on location-specific tumor profilingJulia V Cockle, Karishma Rajani, Shane Zaidi, et al.Nature Medicine|December 11, 2007
Purging metastases in lymphoid organs using a combination of antigen-nonspecific adoptive T cell therapy, oncolytic virotherapy and immunotherapyJian Qiao, Timothy Kottke, Candice Willmon, et al.Science Advances|June 5, 2026
Engagement of the TCR against an oncolytic virus generates a population of effector CAR T cells with potent antitumor activityOlivia Liseth, Elizabeth Appleton, Benjamin Kendall, et al.Nature Medicine|November 19, 2013
Detecting and targeting tumor relapse by its resistance to innate effectors at early recurrenceTimothy Kottke, Nicolas Boisgerault, Rosa Maria Diaz, et al.Molecular Therapy : the Journal of the American Society of Gene Therapy|December 30, 2014
Mutated BRAF Emerges as a Major Effector of Recurrence in a Murine Melanoma Model After Treatment With Immunomodulatory AgentsShane Zaidi, Miran Blanchard, Kevin Shim, et al.Research Square|December 4, 2023
Chimerization of the Anti-Viral CD8+ T Cell Response with A Broad Anti-Tumor T Cell Response Reverses Inhibition of Checkpoint Blockade Therapy by Oncolytic VirotherapyRichard Vile, Mason Webb, Jacob van Vloten, et al.Pageof 20